BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khandelwal M, Anand V, Appunni S, Seth A, Singh P, Mathur S, Sharma A. Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Mol Cell Biochem 2018;446:105-14. [PMID: 29368096 DOI: 10.1007/s11010-018-3278-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Singh A, Gupta N, Khandakar H, Kaushal S, Seth A, Pandey RM, Sharma A. Autophagy-associated HMGB-1 as a novel potential circulating non-invasive diagnostic marker for detection of Urothelial Carcinoma of Bladder. Mol Cell Biochem 2021. [PMID: 34796446 DOI: 10.1007/s11010-021-04299-8] [Reference Citation Analysis]
2 Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics 2021;13:166. [PMID: 34452630 DOI: 10.1186/s13148-021-01154-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bin Y, Ding Y, Xiao W, Liao A. RASSF1A: A promising target for the diagnosis and treatment of cancer. Clin Chim Acta 2020;504:98-108. [PMID: 31981586 DOI: 10.1016/j.cca.2020.01.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sriraman A, Debnath TK, Xhemalce B, Miller KM. Making it or breaking it: DNA methylation and genome integrity. Essays Biochem 2020;64:687-703. [PMID: 32808652 DOI: 10.1042/EBC20200009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
5 Hu J, Wang X, Chen F, Ding M, Dong M, Yang W, Yin M, Wu J, Zhang L, Fu X, Sun Z, Li L, Wang X, Li X, Guo S, Zhang D, Lu X, Leng Q, Zhang M, Zhu L, Zhang X, Chen Q. Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. Front Oncol 2021;11:687374. [PMID: 34222013 DOI: 10.3389/fonc.2021.687374] [Reference Citation Analysis]
6 Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G, Light M, Whitehead A, Ellis D, Sarwar N, Enting D, Birtle A, Johnson B, Huddart R, Griffiths G. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clin Cancer Res 2021;27:1882-92. [PMID: 33472913 DOI: 10.1158/1078-0432.CCR-20-3946] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li CL, Li J, Gong SY, Huang M, Li R, Xiong GX, Wang F, Zou QM, Qi Q, Yin XX. Targeting the ILK/YAP axis by LFG-500 blocks epithelial-mesenchymal transition and metastasis. Acta Pharmacol Sin 2021. [PMID: 33879841 DOI: 10.1038/s41401-021-00655-y] [Reference Citation Analysis]
8 Singh S, Smith MJ. RAS GTPase signalling to alternative effector pathways. Biochem Soc Trans 2020;48:2241-52. [PMID: 33125484 DOI: 10.1042/BST20200506] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mohajan S, Jaiswal PK, Vatanmakarian M, Yousefi H, Sankaralingam S, Alahari SK, Koul S, Koul HK. Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett 2021;507:112-23. [PMID: 33737002 DOI: 10.1016/j.canlet.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu M, Sheng L, Cheng M, Zhang H, Jiang Y, Lin S, Liang Y, Zhu F, Liu Z, Zhang Y, Zhang X, Gao Q, Chen D, Li J, Li Y. Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. Oncogene 2019;38:5425-39. [PMID: 30918330 DOI: 10.1038/s41388-019-0799-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
11 Khandelwal M, Anand V, Appunni S, Seth A, Singh P, Mathur S, Sharma A. RASSF1A-Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target. Mol Cell Biochem 2020;464:51-63. [PMID: 31754973 DOI: 10.1007/s11010-019-03648-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Nunes SP, Henrique R, Jerónimo C, Paramio JM. DNA Methylation as a Therapeutic Target for Bladder Cancer. Cells 2020;9:E1850. [PMID: 32784599 DOI: 10.3390/cells9081850] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
13 Wang J, Zhang X, Yang F, Yang Y, Wang T, Liu W, Zhou H, Zhao W. RASSF1A Enhances Chemosensitivity of NSCLC Cells Through Activating Autophagy by Regulating MAP1S to Inactivate Keap1-Nrf2 Pathway. Drug Des Devel Ther 2021;15:21-35. [PMID: 33442234 DOI: 10.2147/DDDT.S269277] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]